Facille法思丽品牌怎么样 申请店铺

更新时间:2023-03-31
Facille法思丽是哪个国家的品牌?「Facille法思丽」是科妍生物科技股份有限公司旗下著名品牌。该品牌发源于台湾,由创始人韩开程在2001期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
Facille法思丽怎么样

FACILLE法思丽,是来自宝岛台湾的注射用修饰透明质酸钠凝胶,与风靡全球近十年的海德密丝(Hya-Dermis)玻尿酸是同一个厂家生产。FACILLE法思丽经过独家CHAP交联透明质酸平台专利对海德密丝(Hya-Dermis)进行了全新升级,提高了颗粒紧密度,增强了粘弹性。2014年,“FACILLE法思丽”正式进入中国大陆。

2016年,雀巢皮肤健康公司旗下高德美公司全权代理FACILLE®法思丽®国内业务。生产企业:科妍生物科技股份有限公司。

法思丽有什么作用呢?简单来说,法思丽是一款安全而高效的皮下填充剂,可以用于填充面部皱纹,进行面部塑形,随着时间流逝皮肤内的透明质酸逐渐流失而导致肌肤缺水,皱纹增加,法思丽不仅能使皮肤恢复莹润饱满,也可以使局部五官更加立体,从细微处提升面部美感。

法思丽独家CHAP交联透明质酸平台专利,即采用少量交联剂即可实现高效交联,使得法思丽具有两个其他品牌无法比拟的独特优势。一是创新晶格式透明质酸,可以创造绝佳支撑度,不易移位;二是特有的立体屏障结构,使抗酶降解能力更强,塑形效果更持久。

这两个独特优势令法思丽成为了风靡全球的注射用微整形医美产品。同时,法思丽通过海峡两岸多家医院临床试验,验证产品安全有效。以上种种优势,使得法思丽备受全球使用者的好评。

FACILLE law is a modified sodium hyaluronate gel from Taiwan. It is produced by the same manufacturer as Hyde Mis (Hya-Dermis) hyaluronic acid, which has been popular all over the world for nearly ten years. After the exclusive chap cross-linked hyaluronic acid platform patent, facille fasili has upgraded HYA dermis to improve the particle tightness and viscoelasticity. In 2014, "faith fasili" officially entered the mainland of China. In 2016, Nestle skin health's goldsmith & Co., Ltd. acted as the sole agent for the domestic business of facille ® fasley ®. Manufacturer: Keyan Biotechnology Co., Ltd. What's the use of fasley? In short, fasili is a safe and efficient subcutaneous filler, which can be used to fill facial wrinkles and shape the face. With the passage of time, the hyaluronic acid in the skin is gradually lost, resulting in water shortage and increased wrinkles. Fasili can not only restore the skin to be lustrous and plump, but also make the local facial features more three-dimensional, and improve the beauty of the face from the details. The exclusive chap cross-linking hyaluronic acid platform patent of fasili, that is, the use of a small amount of cross-linking agent can achieve efficient cross-linking, so that fasili has unique advantages that cannot be compared with other brands. The first is the innovative crystal form of hyaluronic acid, which can create excellent support and is not easy to shift; the second is the unique three-dimensional barrier structure, which makes the anti enzyme degradation ability stronger and the shaping effect longer. These two unique advantages make fasili become the most popular injection micro plastic medical products in the world. At the same time, fasili has passed clinical trials in many hospitals across the Taiwan Strait to verify that the product is safe and effective. All of the above advantages make fasili highly praised by users all over the world.

本文链接: https://brand.waitui.com/771bf3af3.html

7×24h 快讯

RoboSense与上汽集团进入规模化量产合作新阶段

36氪获悉,RoboSense速腾聚创正式公布与上汽集团旗下汽车品牌飞凡汽车的定点合作。日前,双方合作的车型之一飞凡F7正式上市交付。这标志着,RoboSense速腾聚创与上汽集团的量产车型定点合作全面进入了规模化量产的新阶段。

2小时前

热门中概股美股盘前多数上涨,京东涨超5%

36氪获悉,热门中概股美股盘前多数上涨,截至发稿,京东涨超5%,拟分拆京东产发、京东工业于香港联交所主板独立上市;微博涨超3%,拼多多、蔚来、小鹏汽车、爱奇艺涨超1%,B站涨0.49%,理想汽车涨0.24%,百度跌超2%。

2小时前

贵州茅台:2022年净利润627.16亿元,同比增长19.55%

36氪获悉,贵州茅台发布年报,2022年营业收入1240.99亿元,同比增长16.87%;净利润627.16亿元,同比增长19.55%;基本每股收益49.93元。拟10派259.11元。

2小时前

天齐锂业:2022年净利润241.25亿元,同比增长1060.47%

36氪获悉,天齐锂业发布年报,2022年营业收入404.48亿元,同比增长427.82%;净利润241.24亿元,同比增长1060.47%,拟10派30元。

2小时前

亚朵集团上市后首份成绩单:2022年调整后净利润同比增85.6%至2.59亿元

亚朵集团发布2022年第四季度及全年业绩报告。2022年,亚朵集团实现营收22.63亿元,同比增长5.4%;调整后净利润(非公认会计准则)为2.59亿元,同比增长85.6%。截至2022年12月31日,亚朵集团现金及现金等价物为15.89亿元。报告期内,亚朵新开店191家,仅4家关店,在营酒店数量达932家,房间数达10.8万间,均较上年增长25%;场景零售业务增长迅猛,GMV同比增长42%至3.24亿元。

2小时前

本页详细列出关于Facille法思丽的品牌信息,含品牌所属公司介绍,Facille法思丽所处行业的品牌地位及优势。
咨询